Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes

Gary J. Schiller, James L Slack, John D. Hainsworth, James Mason, Mansoor Saleh, David Rizzieri, Dan Douer, Alan F. List

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Purpose: To evaluate the efficacy and safety of arsenic trioxide monotherapy in patients with myelodysplastic syndromes (MDS). Patients and Methods: Patients received arsenic trioxide (0.25 mg/kg/d) on 5 consecutive days per week for 2 weeks, followed by 2 weeks' rest (one cycle). Two patient cohorts were established according to International Prognostic Scoring System risk category: lower-risk (low or intermediate-1) or higher-risk MDS (intermediate-2 or high). For lower-risk MDS, hematologic improvement (HI) was the primary response end point. For higher-risk MDS, additional end points included complete or partial remission. Based on the expected time to response, patients receiving two or more cycles were prospectively evaluated. Results: Hematologic adverse events included neutropenia, thrombocytopenia, and febrile neutropenia. Two patients died during the study due to treatment-related toxicities. Most common grade 3/4 nonhematologic events were pneumonia, fatigue, hemorrhage, pain, and dyspnea. Among patients who received one or more doses (n = 70) or completed two or more cycles (n = 51), the HI rates were 34% and 39% in lower-risk patients, and 6% and 9% in higher-risk patients, respectively; the overall major HI rates were 20% and 22%. One higher-risk patient achieved a complete remission (3%). Major HIs were observed in all hematologic lineages; erythroid responses were the most common. Transfusion independence or reduction by ≥ 50% occurred in 33% of patients dependent on RBC transfusions. The overall median duration of HI was 6.8 months (range, 2 to 40 months). Conclusion: Arsenic trioxide monotherapy has moderate activity against MDS, with a manageable adverse effect profile. The further study of arsenic trioxide in MDS, particularly in combination with other agents, is warranted.

Original languageEnglish (US)
Pages (from-to)2456-2464
Number of pages9
JournalJournal of Clinical Oncology
Volume24
Issue number16
DOIs
StatePublished - Jun 1 2006

Fingerprint

Myelodysplastic Syndromes
Multicenter Studies
arsenic trioxide
Febrile Neutropenia
Neutropenia
Thrombocytopenia
Dyspnea
Fatigue
Pneumonia
Hemorrhage
Safety
Pain

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Schiller, G. J., Slack, J. L., Hainsworth, J. D., Mason, J., Saleh, M., Rizzieri, D., ... List, A. F. (2006). Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. Journal of Clinical Oncology, 24(16), 2456-2464. https://doi.org/10.1200/JCO.2005.03.7903

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. / Schiller, Gary J.; Slack, James L; Hainsworth, John D.; Mason, James; Saleh, Mansoor; Rizzieri, David; Douer, Dan; List, Alan F.

In: Journal of Clinical Oncology, Vol. 24, No. 16, 01.06.2006, p. 2456-2464.

Research output: Contribution to journalArticle

Schiller, GJ, Slack, JL, Hainsworth, JD, Mason, J, Saleh, M, Rizzieri, D, Douer, D & List, AF 2006, 'Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes', Journal of Clinical Oncology, vol. 24, no. 16, pp. 2456-2464. https://doi.org/10.1200/JCO.2005.03.7903
Schiller, Gary J. ; Slack, James L ; Hainsworth, John D. ; Mason, James ; Saleh, Mansoor ; Rizzieri, David ; Douer, Dan ; List, Alan F. / Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 16. pp. 2456-2464.
@article{fe587ef319e843de9ea04af404370fab,
title = "Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes",
abstract = "Purpose: To evaluate the efficacy and safety of arsenic trioxide monotherapy in patients with myelodysplastic syndromes (MDS). Patients and Methods: Patients received arsenic trioxide (0.25 mg/kg/d) on 5 consecutive days per week for 2 weeks, followed by 2 weeks' rest (one cycle). Two patient cohorts were established according to International Prognostic Scoring System risk category: lower-risk (low or intermediate-1) or higher-risk MDS (intermediate-2 or high). For lower-risk MDS, hematologic improvement (HI) was the primary response end point. For higher-risk MDS, additional end points included complete or partial remission. Based on the expected time to response, patients receiving two or more cycles were prospectively evaluated. Results: Hematologic adverse events included neutropenia, thrombocytopenia, and febrile neutropenia. Two patients died during the study due to treatment-related toxicities. Most common grade 3/4 nonhematologic events were pneumonia, fatigue, hemorrhage, pain, and dyspnea. Among patients who received one or more doses (n = 70) or completed two or more cycles (n = 51), the HI rates were 34{\%} and 39{\%} in lower-risk patients, and 6{\%} and 9{\%} in higher-risk patients, respectively; the overall major HI rates were 20{\%} and 22{\%}. One higher-risk patient achieved a complete remission (3{\%}). Major HIs were observed in all hematologic lineages; erythroid responses were the most common. Transfusion independence or reduction by ≥ 50{\%} occurred in 33{\%} of patients dependent on RBC transfusions. The overall median duration of HI was 6.8 months (range, 2 to 40 months). Conclusion: Arsenic trioxide monotherapy has moderate activity against MDS, with a manageable adverse effect profile. The further study of arsenic trioxide in MDS, particularly in combination with other agents, is warranted.",
author = "Schiller, {Gary J.} and Slack, {James L} and Hainsworth, {John D.} and James Mason and Mansoor Saleh and David Rizzieri and Dan Douer and List, {Alan F.}",
year = "2006",
month = "6",
day = "1",
doi = "10.1200/JCO.2005.03.7903",
language = "English (US)",
volume = "24",
pages = "2456--2464",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "16",

}

TY - JOUR

T1 - Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes

AU - Schiller, Gary J.

AU - Slack, James L

AU - Hainsworth, John D.

AU - Mason, James

AU - Saleh, Mansoor

AU - Rizzieri, David

AU - Douer, Dan

AU - List, Alan F.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Purpose: To evaluate the efficacy and safety of arsenic trioxide monotherapy in patients with myelodysplastic syndromes (MDS). Patients and Methods: Patients received arsenic trioxide (0.25 mg/kg/d) on 5 consecutive days per week for 2 weeks, followed by 2 weeks' rest (one cycle). Two patient cohorts were established according to International Prognostic Scoring System risk category: lower-risk (low or intermediate-1) or higher-risk MDS (intermediate-2 or high). For lower-risk MDS, hematologic improvement (HI) was the primary response end point. For higher-risk MDS, additional end points included complete or partial remission. Based on the expected time to response, patients receiving two or more cycles were prospectively evaluated. Results: Hematologic adverse events included neutropenia, thrombocytopenia, and febrile neutropenia. Two patients died during the study due to treatment-related toxicities. Most common grade 3/4 nonhematologic events were pneumonia, fatigue, hemorrhage, pain, and dyspnea. Among patients who received one or more doses (n = 70) or completed two or more cycles (n = 51), the HI rates were 34% and 39% in lower-risk patients, and 6% and 9% in higher-risk patients, respectively; the overall major HI rates were 20% and 22%. One higher-risk patient achieved a complete remission (3%). Major HIs were observed in all hematologic lineages; erythroid responses were the most common. Transfusion independence or reduction by ≥ 50% occurred in 33% of patients dependent on RBC transfusions. The overall median duration of HI was 6.8 months (range, 2 to 40 months). Conclusion: Arsenic trioxide monotherapy has moderate activity against MDS, with a manageable adverse effect profile. The further study of arsenic trioxide in MDS, particularly in combination with other agents, is warranted.

AB - Purpose: To evaluate the efficacy and safety of arsenic trioxide monotherapy in patients with myelodysplastic syndromes (MDS). Patients and Methods: Patients received arsenic trioxide (0.25 mg/kg/d) on 5 consecutive days per week for 2 weeks, followed by 2 weeks' rest (one cycle). Two patient cohorts were established according to International Prognostic Scoring System risk category: lower-risk (low or intermediate-1) or higher-risk MDS (intermediate-2 or high). For lower-risk MDS, hematologic improvement (HI) was the primary response end point. For higher-risk MDS, additional end points included complete or partial remission. Based on the expected time to response, patients receiving two or more cycles were prospectively evaluated. Results: Hematologic adverse events included neutropenia, thrombocytopenia, and febrile neutropenia. Two patients died during the study due to treatment-related toxicities. Most common grade 3/4 nonhematologic events were pneumonia, fatigue, hemorrhage, pain, and dyspnea. Among patients who received one or more doses (n = 70) or completed two or more cycles (n = 51), the HI rates were 34% and 39% in lower-risk patients, and 6% and 9% in higher-risk patients, respectively; the overall major HI rates were 20% and 22%. One higher-risk patient achieved a complete remission (3%). Major HIs were observed in all hematologic lineages; erythroid responses were the most common. Transfusion independence or reduction by ≥ 50% occurred in 33% of patients dependent on RBC transfusions. The overall median duration of HI was 6.8 months (range, 2 to 40 months). Conclusion: Arsenic trioxide monotherapy has moderate activity against MDS, with a manageable adverse effect profile. The further study of arsenic trioxide in MDS, particularly in combination with other agents, is warranted.

UR - http://www.scopus.com/inward/record.url?scp=33745002275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745002275&partnerID=8YFLogxK

U2 - 10.1200/JCO.2005.03.7903

DO - 10.1200/JCO.2005.03.7903

M3 - Article

C2 - 16651647

AN - SCOPUS:33745002275

VL - 24

SP - 2456

EP - 2464

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 16

ER -